📢 Capivasertib (Truqap) to be listed on the PBS!
The Australian Government has announced that as of 1 October capivasertib (Truqap) will be listed on the Pharmacetucial Benefits Scheme (PBS), providing another vital option for Australians with HR+/HER2- metastatic breast cancer.
This means more equitable access to a treatment that previously cost over $98,000.
This decision addresses an urgent need for effective treatments and provides another vital option for patients when their cancer has developed resistance to existing therapies.
BCNA remains committed to fighting for equitable access to innovative treatments and supporting those living with metastatic breast cancer through every step of their journey.
Read more about the announcement at https://www.bcna.org.au/latest-news/bcna-news/government-announce-access-to-capivasertib-truqap-another-option-for-those-living-with-metastatic-breast-cancer/